Occurrence and characterization of Pain in immune-mediated neuropathies: A multicentre prospective study

European Journal of Neurology

Volumn 18, Issue 1, 2011, Pages 177-183

  Pazzaglia, C ^a,b   Briani, C ^c   Orazio, E N ^d,e   Caliandro, P ^a,b   Granata, G ^a,b   Tonali, P A ^a,b   Padua, L ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Immune mediated neuropathies; Neuropathic pain; Pain questionnaires; Peripheral nervous system

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; DISEASE SEVERITY; DYSESTHESIA; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; NEUROPATHIC PAIN; NEUROPATHY; PAIN ASSESSMENT; PARESTHESIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE;

ANALYSIS OF VARIANCE; FEMALE; HUMANS; MALE; PAIN; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 78650159993     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03108.x     Document Type: Article

References (42)

1. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain. Redefinition and a grading system for clinical and research purposes. Neurology 2008; 18: 1630-1635.
2. MacDonald BK, Cockerell OC, Sander JWAS, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000; 123: 665-676.
3. Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med 2007; 2: S50-S62.
4. Hall GC, Carroll D, Parry D, McQuay HJ. Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain 2006; 122: 156-162.
5. Nurmikko TJ, Eldridge PR. Trigeminal neuralgia -pathophysiology, diagnosis and current treatment. Br J Anaesth 2001; 87: 117-132.
6. Widar M, Ahlstrom G. Disability after a stroke and the influence of long-term pain on everyday life. Scand J Caring Sci 2002; 16: 302-310.
7. Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis - prevalence and clinical characteristics. Eur J Pain 2005; 9: 531-542.
8. Boukhris S, Magy L, Khalil M, Sindou P, Vallat JM. Pain as the presenting symptom of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). J Neurol Sci 2007; 2: 33-38.
9. Ruts L, van Koningsveld R, Jacobs BC, van Doorn PA. Determination of pain and response to methylprednisolone in Guillain-Barré syndrome. J Neurol 2007; 10: 1318-1322.
10. Yamamoto M, Ito Y, Mitsuma N, Hattori N, Sobue G. Pain-related differential expression of NGF, GDNF, IL-6, and their receptors in human vasculitic neuropathies. Intern Med 2003; 11: 1100-1103.
11. Jensen TS, Baron R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain 2003; 102: 1-8.
12. Hughes RA, Bouche P, Cornblath DR, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006; 13: 326-332.
13. Alam TA, Chaudhry V, Cornblath DR. Electrophysiological studies in the Guillain-Barré syndrome: distinguishing subtypes by published criteria. Muscle Nerve 1998; 21: 1275-1279.
14. Steck AJ, Stalder AK, Renaud S. Anti-myelin-associated glycoprotein neuropathy. Curr Opin Neurol 2006; 19: 458-463.
15. Van Schaik IN, Bouche P, Illa I, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol 2006; 13: 802-808.
16. Gorson KC. Vasculitic neuropathies: an update. Neurologist 2007; 13: 12-19.
17. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571.
18. Leuchter AF, Husain MM, Cook IA, et al. Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. Psychol Med 2009; 3: 1-13.
19. Downie WW, Leatham PA, Rhind VM, Wright V, Branco JA, Anderson JA. Studies with pain rating scales. Ann Rheum Dis 1978; 37: 378-381.
20. Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic Pain diagnostic questionnaire (DN4). Pain 2005; 114: 29-36.
21. Portenoy R. Development and testing of a neuropathic pain screening questionnaire: ID Pain. Curr Med Res Opin 2006; 8: 1555-1565.
22. Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 2004; 3: 248-257.
23. Padua L, Briani C, Jann S, et al. Validation of the Italian version of the Neuropathic Pain Symptom Inventory in peripheral nervous system diseases. Neurol Sci 2009; 2: 99-106.
24. De Petrocellis L, Davis JB, Di Marzo V. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett 2001; 506: 253-256.
25. Ranieri M, Sciuscio M, Cortese AM, et al. The use of alpha-lipoic acid (ALA), gamma linolenic acid (GLA) and rehabilitation in the treatment of back pain: effect on health-related quality of life. Int J Immunopathol Pharmacol 2009; 22: 45-50.
26. Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuropathic pain. Brain Res Rev 2006; 51: 240-264.
27. Sadosky A, McDermott AM, Brandenburg NA, Strauss M. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract 2008; 1: 45-56.
28. McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 2006; 10: 127-135.
29. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life. Review and implications. Neurology 2007; 68: 1178-1182.
30. Barbieri S, Sandroni P, Nobile-Orazio E, et al. Small fibre involvement in neuropathy associated with IgG, IgA and IgM monoclonal gammopathy. Electromyogr Clin Neurophysiol 1995; 1: 39-44.
31. Nobile-Orazio E. Antigenic determinants in IgM paraprotein-related neuropathies. Clin Lymphoma Myeloma 2009; 9: 107-109.
32. Cocito D, Paolasso I, Pazzaglia C, et al. Pain affects the quality of life of neuropathic patients. Neurol Sci 2006; 27: 155-160.
33. Ochoa JL, Torebjörk HE. Paraesthesiae from ectopic impulse generation in human sensory nerves. Brain 1980; 103: 835-853.
34. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999; 353: 1959-1964.
35. Lee JE, Shun CT, Hsieh SC, Hsieh ST. Skin denervation in vasculitic neuropathy. Arch Neurol 2005; 10: 1570-1573.
36. Rekand T, Gramstad A, Vedeler CA. Fatigue, pain and muscle weakness are frequent after Guillain-Barré syndrome and poliomyelitis. J Neurol 2009; 256: 349-354.
37. Ruts L, Rico R, van Koningsveld R, et al. Pain accompanies pure motor Guillain-Barré syndrome. J Peripher Nerv Syst 2008; 13: 305-306.
38. Chiang MC, Lin YH, Pan CL, Tseng TJ, Lin WM, Hsieh ST. Cutaneous innervation in chronic inflammatory demyelinating polyneuropathy. Neurology 2002; 7: 1094-1098.
39. Pan CL, Tseng TJ, Lin YH, Chiang MC, Lin WM, Hsieh ST. Cutaneous innervation in Guillain-Barré syndrome: pathology and clinical correlations. Brain 2003; 2: 386-397.
40. Baron R, Tolle TR, Gockel U, Brosz M, Freynhagen R. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: differences on demographic data and sensory symptoms. Pain 2009; 146: 34-40.
41. Attal N, Fermanian C, Fermanian J, Lanteri-Minet M, Alchaar H, Bouhassira D. Neuropathic pain: are there distinct sub-types depending on the aetiology or anatomical lesion? Pain 2008; 138: 343-353.
42. Moreira de Barros GA. Methods of evaluation of the effectiveness of the treatments for pain. Drugs Today (Barc) 2009; 45: 13-17.